Seeking Alpha

Sarepta Therapeutics (SRPT -7.6%) reversed an early gain to continue its descent lower today,...

Sarepta Therapeutics (SRPT -7.6%) reversed an early gain to continue its descent lower today, despite issuing a positive update from Phase IIb testing of its eteplirsen drug treatment for Duchenne muscular dystrophy. The company says data continues to show a statistically significant clinical benefit for patients after 62 weeks. Unfortunately, the stock has been in a steady decline since the company gave its presentation at the Deutsche Bank 2012 dbAccess BioFEST Conference in Boston on Tuesday.
From other sites
Comments (9)
  • HYDRO
    , contributor
    Comments (27) | Send Message
     
    Does anyone know why this stock in tanking?
    7 Dec 2012, 05:00 PM Reply Like
  • User 318261
    , contributor
    Comment (1) | Send Message
     
    Yes. To get rid of the weak hands
    8 Dec 2012, 03:00 AM Reply Like
  • arjbda
    , contributor
    Comments (2) | Send Message
     
    There are many people in this for the short term. My thought is that if it helps all the sufferers first that initself is a reward and the fiunacial rewards will be great.

     

    thank youy

     

    thank you
    8 Dec 2012, 02:18 AM Reply Like
  • lcharlie007
    , contributor
    Comments (2) | Send Message
     
    is it a good news? 62-week result is even worse than the 48-week one. 62 - 48 = 24 weeks are trash time.
    8 Dec 2012, 02:33 AM Reply Like
  • Angerame1
    , contributor
    Comment (1) | Send Message
     
    The Deutsche Bank presentation addressed more of the tactical issues that need to be addressed prior to launch of the product.
    While the CEO did not come out and say there was no chance of early approval by the FDA (which he should not even infer), he did say there was going to be a meeting in Q1 to discuss options with the FDA.
    Apparently the in-and-out, short-term investor wasn't impressed with this longer view of the company presented at the conference, hence the decrease in stock price over the past few days.

     

    The company, and hence the stock, is going to be a long term success. The day trader is not tolerant of timelines longer than the next 30 days. The 62 week information released today confirms the long term successful direction of the company. It's just going to take awhile to get there.
    8 Dec 2012, 02:45 AM Reply Like
  • jimgutner
    , contributor
    Comments (70) | Send Message
     
    Are they weak hands or are they correct? If you think you know, you are deluding yourself. Nobody has the Sarepta crystal ball - not even the company. There are a limited number of paths this can follow and each one of them is possible.
    8 Dec 2012, 09:29 AM Reply Like
  • HYDRO
    , contributor
    Comments (27) | Send Message
     
    We are all here to make money but I do hope for the sake of these kids this drug works. You can almost feel guilty if you short this company.I hope they find a cure at the end of it all..
    8 Dec 2012, 10:17 AM Reply Like
  • budrolfs
    , contributor
    Comments (2) | Send Message
     
    At 48 weeks; Eteplirsen appeared to be a REVERSAL DRUG, because the test patients walked even further than they did PRE-TEST. At 52 weeks, it appeared to be more like a STABILIZING DRUG, or God forbid; only one with temporary effect long term. With only about 4 kids in the long term test group; ANY THING is possible I suppose. BUT...go to YouTube and enter Max McNary. He is one of the test kids who could not even open a can of soda a year ago; and on Dec, 5th, his mom videoed him dancing around his kitchen. NO WAY was he STABILIZED! That being said; short term stock price will go to $20 IF it doesn't HOLD at the $25 LEVEL. DISCLOSURE: I've been in since 66 cents, so I can wait this correction out.
    8 Dec 2012, 12:45 PM Reply Like
  • HYDRO
    , contributor
    Comments (27) | Send Message
     
    Does anyone have a idea why SRPT going to sell shares? Is this good.bad or ugly for the longs in this position?
    12 Dec 2012, 05:56 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs